Cutler Group LP Immuno Gen, Inc. Call Options Transaction History

Cutler Group LP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$12.46 - $29.95 $78,498 - $188,685	6,300 Added 1260.0%	6,800 $36,000
Q3 2023 Nov 07, 2023	SELL	$14.09 - $19.87 $109,902 - $154,986	-7,800 Reduced 93.98%	500 $3,000
Q2 2023 Jul 18, 2023	BUY	$3.75 - $20.05 $19,500 - $104,260	5,200 Added 167.74%	8,300 $65,000
Q1 2023 May 01, 2023	BUY	$3.67 - $4.92 $2,569 - $3,444	700 Added 29.17%	3,100 $2,000
Q4 2022 Feb 07, 2023	BUY	$4.55 - $6.31 $455 - $631	100 Added 4.35%	2,400 $0
Q3 2022 Oct 25, 2022	SELL	$4.48 - $6.47 $4,480 - $6,470	-1,000 Reduced 30.3%	2,300 $0
Q2 2022 Aug 04, 2022	SELL	$3.15 - $5.76 $315 - $576	-100 Reduced 2.94%	3,300 $3,000
Q1 2022 Apr 14, 2022	SELL	$4.26 - $7.48 $49,416 - $86,768	-11,600 Reduced 77.33%	3,400 $0
Q4 2021 Jan 18, 2022	BUY	$4.75 - $7.5 $28,500 - $45,000	6,000 Added 66.67%	15,000 $10,000
Q2 2021 Jul 19, 2021	BUY	$5.79 - $8.6 $52,110 - $77,400	9,000 New	9,000 $0
Q2 2019 Aug 09, 2019	SELL	$1.8 - $3.3 $29,700 - $54,450	-16,500 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$2.41 - $5.91 $1,446 - $3,546	-600 Reduced 3.51%	16,500 $0
Q4 2017 Jan 17, 2018	SELL	$5.07 - $7.92 $62,868 - $98,208	-12,400 Reduced 42.03%	17,100 $0
Q3 2017 Oct 17, 2017	BUY	$5.4 - $8.47 $159,300 - $249,865	29,500	29,500 $28,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.